President Donald Trump's proposed 2018 budget cuts $5.8 billion from the National Institutes of Health (NIH), about 20% of its current budget. While these numbers represent a request to Congress and not a final agreement, the cuts are a dramatic statement against science as a priority for the administration and for our country.
These cuts, if implemented, may have a greater negative impact on the stem cell research field than the restrictions implemented by former President Bush. Ongoing NIH funding is critical to all biomedical research, including ours at The New York Stem Cell Foundation. Cutting these funds is a major risk for all research, and threatens to slow down or stop potentially lifesaving experiments while also put at risk the jobs of many scientists across the country.
The President has also proposed significant budget cuts to the NIH and other scientific agencies for the remainder of this year’s budget. These drastic measures would be a major step back for the advancement of science and medicine in the United States.
Politico spoke with NYSCF CEO Susan L. Solomon about the proposed cuts, read the story here (firewalled) >>
The NYSCF Global Stem Cell Array was a central talking point in both an exclusive interview and digital panel with The Regenerative Medicine Network. NYSCF Senior Vice President of Research Dr. Scott Noggle spoke with RegMedNet about how he became interested in stem cell research, NYSCF's growth in the past eleven years including construction and launch of the NYSCF Array, and NYSCF’s ongoing efforts to continually improve stem cell production and derivation using cutting edge automation.
In addition to the interview with Dr. Noggle, NYSCF’s Dr. Daniel Paull, Vice President, Automation Systems & Stem Cell Biology, highlighted the importance of the NYSCF Array in a RegMedNet digital panel discussing induced pluripotent stem cell derivation and applications in research. The panel covered challenges in stem cell derrivation, future potential applications in regenerative medicine, and regulatory challenges. Fellow panelists included Lia Kent of Biological Industries USA, Dr. Yvonne Mica of Thermo Fisher Scientific, and Dr. Fiona Watt of Centre for Stem Cells & Regenerative Medicine at King’s College London.
Adult cells can be reprogrammed into stem cells through a technique called somatic cell nuclear transfer where the nucleus of the adult cell is transferred into an enucleated oocyte or egg cell. However, this process often causes the cell to stop dividing and growing. NYSCF – Robertson Stem Cell Investigator Dr. Dieter Egli and a team of researchers at Columbia University Medical Center studied why this developmental arrest happens. Published in Nature Cell Biology, the scientists showed that cell-type-specific features of cell cycle progression are different enough from one another to prevent the transition from one cell type to another during reprogramming, independent of gene expression.
It is not yet known which type of stem cell derivation will result in the best cells for use in research, drug toxicity testing, and future cell replacement therapies. Understanding the causes and affects of reprogramming techniques on DNA and genome expression is a critical step towards better research, and new treatments and therapies.